BACKGROUND: Brain metastases are most common in adults with lung cancer, predicting uniformly poor patient outcome, with a median survival of only months. Despite their frequency and severity, very little is known about tumorigenesis in brain metastases. METHODS: We applied previously developed primary solid tumor-initiating cell models to the study of brain metastases from the lung to evaluate the presence of a cancer stem cell population. Patient-derived brain metastases (n = 20) and the NCI-H1915 cell line were cultured as stem-enriching tumorspheres. We used in vitro limiting-dilution and sphere-forming assays, as well as intracranial human-mouse xenograft models. To determine genes overexpressed in brain metastasis tumorspheres, we performed comparative transcriptome analysis. All statistical analyses were two-sided. RESULTS: Patient-derived brain metastasis tumorspheres had a mean sphere-forming capacity of 33 spheres/2000 cells (SD = 33.40) and median stem-cell frequency of 1/60 (range = 0-1/141), comparable to that of primary brain tumorspheres (P = .53 and P = .20, respectively). Brain metastases also expressed CD15 and CD133, markers suggestive of a stemlike population. Through intracranial xenotransplantation, brain metastasis tumorspheres were found to recapitulate the original patient tumor heterogeneity. We also identified several genes overexpressed in brain metastasis tumorspheres as statistically significant predictors of poor survival in primary lung cancer. CONCLUSIONS: For the first time, we demonstrate the presence of a stemlike population in brain metastases from the lung. We also show that NCI-H1915 tumorspheres could be useful in studying self-renewal and tumor initiation in brain metastases. Our candidate genes may be essential to metastatic stem cell populations, where pathway interference may be able to transform a uniformly fatal disease into a more localized and treatable one.
BACKGROUND:Brain metastases are most common in adults with lung cancer, predicting uniformly poor patient outcome, with a median survival of only months. Despite their frequency and severity, very little is known about tumorigenesis in brain metastases. METHODS: We applied previously developed primary solid tumor-initiating cell models to the study of brain metastases from the lung to evaluate the presence of a cancer stem cell population. Patient-derived brain metastases (n = 20) and the NCI-H1915 cell line were cultured as stem-enriching tumorspheres. We used in vitro limiting-dilution and sphere-forming assays, as well as intracranial human-mouse xenograft models. To determine genes overexpressed in brain metastasis tumorspheres, we performed comparative transcriptome analysis. All statistical analyses were two-sided. RESULTS:Patient-derived brain metastasis tumorspheres had a mean sphere-forming capacity of 33 spheres/2000 cells (SD = 33.40) and median stem-cell frequency of 1/60 (range = 0-1/141), comparable to that of primary brain tumorspheres (P = .53 and P = .20, respectively). Brain metastases also expressed CD15 and CD133, markers suggestive of a stemlike population. Through intracranial xenotransplantation, brain metastasis tumorspheres were found to recapitulate the original patienttumor heterogeneity. We also identified several genes overexpressed in brain metastasis tumorspheres as statistically significant predictors of poor survival in primary lung cancer. CONCLUSIONS: For the first time, we demonstrate the presence of a stemlike population in brain metastases from the lung. We also show that NCI-H1915 tumorspheres could be useful in studying self-renewal and tumor initiation in brain metastases. Our candidate genes may be essential to metastatic stem cell populations, where pathway interference may be able to transform a uniformly fatal disease into a more localized and treatable one.
Authors: Deepak Kanojia; Ramin A Morshed; Lingjiao Zhang; Jason M Miska; Jian Qiao; Julius W Kim; Peter Pytel; Irina V Balyasnikova; Maciej S Lesniak; Atique U Ahmed Journal: Mol Cancer Ther Date: 2015-02-27 Impact factor: 6.261
Authors: Anna S Berghoff; Yunxiang Liao; Matthia A Karreman; Ayseguel Ilhan-Mutlu; Katharina Gunkel; Martin R Sprick; Christian Eisen; Tobias Kessler; Matthias Osswald; Susanne Wünsche; Manuel Feinauer; Brunhilde Gril; Frederic Marmé; Laura L Michel; Zuszanna Bago-Horvath; Felix Sahm; Natalia Becker; Michael O Breckwoldt; Gergely Solecki; Miriam Gömmel; Lulu Huang; Petra Rübmann; Carina M Thome; Miriam Ratliff; Andreas Trumpp; Patricia S Steeg; Matthias Preusser; Wolfgang Wick; Frank Winkler Journal: Mol Cancer Res Date: 2020-12-22 Impact factor: 6.333
Authors: Mohini Singh; Neha Garg; Chitra Venugopal; Robin Hallett; Tomas Tokar; Nicole McFarlane; Sujeivan Mahendram; David Bakhshinyan; Branavan Manoranjan; Parvez Vora; Maleeha Qazi; Carolynn C Arpin; Brent Page; Sina Haftchenary; David A Rosa; Ping-Shan Lai; Rodolfo F Gómez-Biagi; Ahmed M Ali; Andrew Lewis; Mulu Geletu; Naresh K Murty; John A Hassell; Igor Jurisica; Patrick T Gunning; Sheila K Singh Journal: Oncotarget Date: 2015-09-29